WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 317181
CAS#: 71675-85-9 (free base)
Description: Amisulpride is an atypical antipsychotic used to treat psychosis in schizophrenia and episodes of mania in bipolar disorder. In Italy, it is also used as a treatment for dysthymia. It was introduced by Sanofi-Aventis in the 1990s. Its patent had expired by 2008 and hence generic formulations are now available.Amisulpride function primarily as a D2 and D3 receptor antagonist. It has high affinity for these receptors with dissociation constants of 2.2 nM and 2.4 nM, respectively. Although standard doses used to treat psychosis inhibit dopaminergic neurotransmission, low doses preferentially block inhibitory pre-synaptic autoreceptors.
MedKoo Cat#: 317181
Name: Amisulpride free base
CAS#: 71675-85-9 (free base)
Chemical Formula: C17H27N3O4S
Exact Mass: 369.17223
Molecular Weight: 369.48
Elemental Analysis: C, 55.26; H, 7.37; N, 11.37; O, 17.32; S, 8.68
Amisulpride, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Related CAS #: 81342-13-4 (HCl) 71675-85-9 (free base) 71675-92-8 (S-isomer)
Synonym: Solian; Aminosultopride; Deniban; Amisulprida; Amazeo; Amipride; Amival; Soltus; Sulpitac; Sulprix
IUPAC/Chemical Name: 4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide
InChi Key: NTJOBXMMWNYJFB-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)
SMILES Code: CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC
The following data is based on the product molecular weight 369.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Bonnet U, Taazimi B, Montag M, Ronge R, Gespers H, Kuhlmann R, Grabbe D, Jahn J. Severe acute pancreatitis, neuroleptic malignant syndrome and grand mal seizures associated with elevated amisulpride and low clozapine serum levels. Psychiatr Danub. 2015 Dec;27(4):424-5. PubMed PMID: 26609657.
2: Vinkers CH, Sommer IE. [Amisulpride: a treatment option for psychotic disorders soon to be available in the Netherlands]. Tijdschr Psychiatr. 2015;57(11):830-4. Dutch. PubMed PMID: 26552930.
3: Arora M, Banal R, Praharaj SK, Mahajan V. Amisulpride Augmentation in Acute Catatonia. Am J Ther. 2015 Aug 11. [Epub ahead of print] PubMed PMID: 26270797.
4: Liang Y, Su YA, Zhao ZG, Gao N, Huang JZ, Tang MQ, Li KQ, Yang FD, Yu X, Si TM. Acute Effects of Haloperidol, Amisulpride, and Quetiapine on Bone Turnover Markers in Patients With Schizophrenia. J Clin Psychopharmacol. 2015 Oct;35(5):583-6. doi: 10.1097/JCP.0000000000000379. PubMed PMID: 26270200.
5: Deepak TS, Raveesh BN, Parashivamurthy BM, Kumar MN, Majgi SM, Nagesh HN. Clinical Assessment of Weight Gain with Atypical Antipsychotics - Blonanserin vs Amisulpride. J Clin Diagn Res. 2015 Jun;9(6):FC07-10. doi: 10.7860/JCDR/2015/13007.6066. Epub 2015 Jun 1. PubMed PMID: 26266134; PubMed Central PMCID: PMC4525523.
6: Metzger CD, Wiegers M, Walter M, Abler B, Graf H. Local and Global Resting State Activity in the Noradrenergic and Dopaminergic Pathway Modulated by Reboxetine and Amisulpride in Healthy Subjects. Int J Neuropsychopharmacol. 2015 Jul 25. pii: pyv080. doi: 10.1093/ijnp/pyv080. [Epub ahead of print] PubMed PMID: 26209860.
7: Gros M, Williams M, Llorca M, Rodriguez-Mozaz S, Barceló D, Kookana RS. Photolysis of the antidepressants amisulpride and desipramine in wastewaters: Identification of transformation products formed and their fate. Sci Total Environ. 2015 Oct 15;530-531:434-44. doi: 10.1016/j.scitotenv.2015.05.135. Epub 2015 Jun 8. PubMed PMID: 26068227.
8: Laoutidis ZG, Konstantinidis A, Grohmann R, Luckhaus C, Mobascher J, Cordes J. Reversible Amisulpride-induced Elevation of Creatine Kinase (CK): A Case Series from the German AMSP Pharmacovigilance Project. Pharmacopsychiatry. 2015 Jul;48(4-5):178-81. doi: 10.1055/s-0035-1549997. Epub 2015 May 18. PubMed PMID: 25984709.
9: Bogorni F, Moreira FF, Pimentel EM, Grohs GE, Diaz AP. Amisulpride augmentation for clozapine-refractory positive symptoms: additional benefit in reducing hypersialorrhea. Case Rep Psychiatry. 2015;2015:408179. doi: 10.1155/2015/408179. Epub 2015 Mar 9. PubMed PMID: 25838958; PubMed Central PMCID: PMC4370110.
10: Hong CC, Chen CK, Yeh TC, Chu CS, Chen TY. Amisulpride monotherapy may be a choice of maintenance treatment for patients with both bipolar I disorder and metabolic syndrome. Aust N Z J Psychiatry. 2015 Aug;49(8):757-8. doi: 10.1177/0004867415577438. Epub 2015 Mar 18. PubMed PMID: 25788497.
